Rational Design of a Trimeric April-Based CAR-Binding Domain Enables Efficient Targeting of Multiple Myeloma

Proteomics

Rational Design of a Trimeric April-Based CAR-Binding Domain Enables Efficient Targeting of Multiple Myeloma

Featured Speaker: Andrea Schmidts, Post Doctoral Research Fellow, MD Cellular Immunotherapy Program, MGH Cancer Center and Harvard Medical School

Your data is secure

We keep your personal information safe and do not share it with any third parties. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy. You may unsubscribe at any time.

What's Inside

In this Webinar we discuss:

Discover how a trimeric extracellular moiety of APRIL has enhanced binding to BCMA and TACI compared with monomeric APRIL when incorporated into a CAR

Explore why trimeric APRIL-based CAR are efficient against BCMA-negative multiple myeloma

Learn why T cells transduced with a trimeric APRIL-based CAR are a promising approach for the treatment of multiple myeloma